DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: VANIQA

Summary for Tradename: VANIQA

Patents:1
Applicants:1
NDAs:1
Suppliers: see list2
drug
patent expirations by year for
 VANIQA

Pharmacology for Tradename: VANIQA

Clinical Trials for: VANIQA

Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)
Status: Recruiting Condition: Familial Adenomatous Polyposis

A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP)
Status: Withdrawn Condition: Familial Adenomatous Polyposis

Eflornithine To Prevent Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia
Status: Completed Condition: Cervical Cancer; Precancerous Condition

Acetylsalicylic Acid and Eflornithine in Treating Patients at High Risk for Colorectal Cancer
Status: Recruiting Condition: Adenomatous Polyp

S0820, Adenoma and Second Primary Prevention Trial
Status: Recruiting Condition: Colorectal Neoplasms

Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps
Status: Completed Condition: Precancerous Condition

Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis
Status: Completed Condition: Colorectal Cancer; Familial Adenomatous Polyposis

Eflornithine and/or Diclofenac in Treating Patients With Sun-Damaged Skin
Status: Completed Condition: Non-melanomatous Skin Cancer

Neoadjuvant Eflornithine and Bicalutamide Compared With Eflornithine Alone, Bicalutamide Alone, and No Neoadjuvant Therapy in Treating Patients With Localized Prostate Cancer Undergoing Brachytherapy or Radical Prostatectomy
Status: Completed Condition: Prostate Cancer

Clinical Study to Assess the Tolerability, Feasibility and Effectiveness of Nifurtimox and Eflornithine (NECT) for the Treatment of Trypanosoma Brucei Gambiense Human African Trypanosomiasis (HAT) in the Meningo-encephalitic Phase
Status: Completed Condition: Human African Trypanosomiasis

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Skinmedica
VANIQA
eflornithine hydrochloride
CREAM;TOPICAL021145Jul 27, 2000RXYes5,648,394<disabled><disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc